Recombinant Mouse Thromboxane A2 receptor (Tbxa2r)

What is the basic structure and localization of mouse Tbxa2r?

Mouse Tbxa2r is a G protein-coupled receptor with an expected protein mass of approximately 37.4 kDa. Immunofluorescence studies reveal that Tbxa2r is predominantly localized on the cytoplasmic membrane, with some distribution in perinuclear compartments of cells. In microglia, for instance, the receptor shows primary localization on the plasma membrane with additional presence in cytosolic perinuclear regions . The protein structure includes typical seven-transmembrane domains characteristic of G protein-coupled receptors, with multiple isoforms reported due to alternative splicing .

What signaling pathways are activated by mouse Tbxa2r?

Mouse Tbxa2r primarily signals through:

• ERK (Extracellular signal-Regulated Kinase) pathway: Tbxa2r activation induces dose- and time-dependent ERK phosphorylation, particularly important in microglial activation .

• Rho signaling: Tbxa2r enhances cell migration and invasion by activating Rho signaling, which can be reversed using Rho-associated Kinase (ROCK) inhibitors .

• ERM (Ezrin-Radixin-Moesin) protein activation: Recent research indicates Tbxa2r activates ERM proteins to regulate cell migration, invasion, and metastatic potential .

Methodologically, these pathways can be studied using phosphorylation-specific antibodies in Western blot analysis, pharmacological inhibitors (MEK inhibitor U0126, ROCK inhibitors), and cellular phenotype assays following receptor activation with specific agonists like U46619 .

How does mouse Tbxa2r expression change under pathological conditions?

Tbxa2r expression shows significant upregulation in various pathological conditions:

• Ischemic brain injury: Protein levels increase significantly in ipsilateral mouse brain tissue at 24 hours post-ischemia-reperfusion. Western blot quantification reveals substantial upregulation compared to contralateral hemisphere or sham controls .

• Cancer contexts: Certain cancers show altered expression of Tbxa2r. In breast cancer models, TBXA2R expression correlates with specific subtypes and clinical outcomes .

For quantifying expression changes, researchers should employ:

• Western blotting with specific antibodies

• RT-qPCR for transcript level assessment

• Immunohistochemistry to analyze tissue distribution patterns and co-localization with cell-specific markers (e.g., CD11b for microglia/macrophages in brain tissue)

What factors regulate Tbxa2r transcription and protein stability?

Research indicates several regulatory mechanisms:

• BRCA1-mediated transcriptional repression: BRCA1 knockdown increases TBXA2R mRNA and promoter activities, with c-Myc being required for this BRCA1-mediated transcriptional repression .

• Post-translational modifications: Although not fully characterized for mouse Tbxa2r specifically, G protein-coupled receptors typically undergo phosphorylation, ubiquitination, and internalization following ligand binding.

Methodologically, researchers should consider:

• Promoter-reporter assays to study transcriptional regulation

• ChIP (Chromatin Immunoprecipitation) to identify transcription factor binding

• Pulse-chase experiments to assess protein turnover rates

How can mouse Tbxa2r function be effectively studied in neuroinflammation models?

To study Tbxa2r in neuroinflammation:

• Primary microglia and microglial cell line systems: Use BV2 cells or primary microglia cultures to assess the direct effects of Tbxa2r activation. Treatment with the TP agonist U46619 enhances inflammatory mediator production (IL-1β, IL-6, iNOS) and NO release, which can be quantified by ELISA, qPCR, and Griess assay .

• Co-culture systems: Employ neuronal-microglial co-culture models (e.g., SH-SY5Y cells with microglia) to assess how Tbxa2r activation in microglia affects neuronal viability and function. Conditioned media experiments reveal that U46619-treated BV2 cells produce factors that decrease neuronal cell viability and induce apoptotic morphological changes .

• Pharmacological modulation: Use specific agonists (U46619) and antagonists (SQ29548) to manipulate receptor activity, combined with pathway inhibitors (U0126 for MEK/ERK) to delineate downstream signaling .

• In vivo models: Utilize ischemia-reperfusion models (e.g., transient middle cerebral artery occlusion) to examine Tbxa2r expression changes and function in neuroinflammatory contexts .

What methodologies are most effective for studying Tbxa2r in immune cell function?

To investigate Tbxa2r in immune regulation:

How does mouse Tbxa2r contribute to cancer progression and metastasis?

Evidence supports multiple roles for Tbxa2r in cancer:

• Cell survival promotion: TBXA2R functions as a survival factor specifically for certain cancer types. Knockdown of TBXA2R causes dramatic cell death in Triple Negative Breast Cancer (TNBC) cells, identifying it as a potential therapeutic target .

• Migration and invasion: TBXA2R enhances cancer cell migration and invasion through activation of Rho signaling. These phenotypes can be reversed using ROCK inhibitors, suggesting a mechanistic pathway through which TBXA2R promotes metastatic behavior .

• Protection from DNA damage: TBXA2R protects cancer cells from DNA damage by negatively regulating reactive oxygen species (ROS) levels, potentially contributing to therapy resistance .

• Metastatic colonization: Recent research indicates TBXA2R activation enhances metastatic colonization in vivo, suggesting its importance in the later stages of cancer progression .

Methodologically, researchers should consider:

• In vitro migration and invasion assays

• ROS measurement using fluorescent probes

• Rho activation assays

• In vivo metastasis models

What are the optimal approaches for generating and validating recombinant mouse Tbxa2r for functional studies?

When generating recombinant mouse Tbxa2r:

• Expression systems: Consider mammalian expression systems (HEK293, CHO cells) for proper folding and post-translational modifications of the receptor. These systems more closely recapitulate the native environment compared to bacterial or insect cell systems.

• Tagging strategies:

  • N-terminal tags may interfere with signal peptide processing

  • C-terminal tags are generally preferred for GPCRs but verify that they don't disrupt G-protein coupling

  • Common tags include FLAG, HA, or His for detection and purification

• Validation approaches:

  • Binding assays with known ligands (U46619)

  • Functional assays measuring downstream signaling (calcium flux, ERK phosphorylation)

  • Surface expression verification via immunofluorescence or flow cytometry

  • Western blotting to confirm expected molecular weight (approximately 37.4 kDa)

• Mutagenesis studies: Generate point mutations in key residues to assess structure-function relationships and binding properties

How do mouse and human TBXA2R differ in structure and function?

Understanding species differences is crucial for translational research:

• Sequence homology: Mouse and human TBXA2R share significant sequence homology, though species-specific differences exist in certain domains that may affect ligand binding and signaling properties.

• Isoform expression: Both species express multiple isoforms due to alternative splicing, though the relative abundance and tissue distribution of these isoforms may differ .

• Signaling conservation: Core signaling pathways (ERK activation, Rho signaling) appear conserved between species, suggesting functional similarity despite structural differences .

• Pharmacological responses: Mouse and human receptors may show differential sensitivity to certain agonists and antagonists, necessitating careful validation when translating findings between species.

When conducting comparative studies, researchers should:

• Perform sequence alignment analysis

• Compare pharmacological profiles using dose-response curves

• Validate antibody cross-reactivity between species

• Consider species-specific differences in downstream effector coupling

What are the key considerations when using recombinant mouse Tbxa2r models to study human disease?

When translating findings from mouse to human systems:

What are the most reliable detection methods for mouse Tbxa2r in different experimental contexts?

Optimal detection strategies vary by application:

• Immunodetection approaches:

  • Western blotting: Effective for quantifying total protein levels in tissue or cell lysates

  • Immunofluorescence: Useful for determining subcellular localization (predominantly membrane)

  • Flow cytometry: Appropriate for quantifying surface expression levels in intact cells

  • Immunohistochemistry: Valuable for tissue distribution analysis and co-localization studies

• Transcript analysis:

  • RT-qPCR: Provides sensitive quantification of mRNA expression

  • RNA-Seq: Offers comprehensive transcriptomic analysis including isoform detection

  • In situ hybridization: Allows visualization of transcript localization in tissue sections

• Functional detection:

  • Calcium flux assays: Measure receptor activation in live cells

  • ERK phosphorylation: Downstream readout of receptor activation

  • Rho activation assays: Assess pathway-specific activation

How can researchers effectively modulate mouse Tbxa2r activity in experimental systems?

Multiple approaches are available:

• Pharmacological modulation:

  • Agonists: U46619 is a commonly used TP agonist for receptor activation

  • Antagonists: SQ29548 effectively blocks TP signaling

  • Pathway inhibitors: U0126 (MEK/ERK inhibition) and ROCK inhibitors can block downstream effects

• Genetic approaches:

  • siRNA/shRNA: For transient or stable knockdown

  • CRISPR-Cas9: For complete knockout or precise mutations

  • Overexpression systems: For gain-of-function studies

• Experimental design considerations:

  • Timing: Acute versus chronic modulation may yield different outcomes

  • Dose-response: Establish full dose-response curves rather than single concentrations

  • Specificity controls: Include receptor-negative cells to confirm specificity